MedTrace Logo

Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00671073 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 427

Last updated 2019-09-19

No results posted yet for this study

Summary

This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or placebo.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Oglemilast

Oglemilast low dose, oral administration, once daily for 12 weeks

DRUG

Placebo

Placebo, oral administration, once daily for 12 weeks

DRUG

Oglemilast

Oglemilast middle dose, oral administration, once daily for 12 weeks

DRUG

Oglemilast

Oglemilast high dose, oral administration, once daily for 12 weeks

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Brian T Maurer, MS · Forest Laboratories

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-05
Primary Completion
2009-05-15
Completion
2009-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00671073 on ClinicalTrials.gov